Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
Rosenstock J, Wysham C, Frías JP, et al. The Lancet 2021;398:143-155.
What it found
HbA1c fell by 1.87% to 2.07% vs a rise of 0.04% with placebo; 87-92% reached an HbA1c below 7.0% vs 20%. Weight loss ranged from 7.0 to 9.5 kg. Nausea (12-18% vs 6%) and diarrhoea (12-14% vs 8%) were the most frequent side effects; no severe hypoglycaemia.
Limitations
People early in type 2 diabetes on no other glucose-lowering drugs; 40 weeks only.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.